---
title: "Verona Pharma (VRNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VRNA.US.md"
symbol: "VRNA.US"
name: "Verona Pharma"
industry: "Pharmaceuticals"
datetime: "2026-05-21T15:00:39.708Z"
locales:
  - [en](https://longbridge.com/en/quote/VRNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VRNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VRNA.US.md)
---

# Verona Pharma (VRNA.US)

## Company Overview

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: C (0.59)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 117 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 35.28% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 221673000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -36.36% | E |
| Profit Margin | -36.62% | E |
| Gross Margin | 95.39% | A |
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 35.28% | B |
| Total Assets YoY | 31.96% | A |
| Net Assets YoY | 65.37% | A |
| Cash Flow Margin | -273.04% | E |
| OCF YoY | 0.00% | D |
| Turnover | 0.44 | C |
| Gearing Ratio | 51.42% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Verona Pharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "35.28%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "221673000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-36.36%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.62%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "95.39%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "35.28%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "31.96%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "65.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-273.04%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "51.42%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -113.50 | 227/190 | - | - | - |
| PB | 33.11 | 185/190 | 33.11 | 33.11 | 33.11 |
| PS (TTM) | 41.57 | 143/190 | 56.97 | 41.57 | 41.57 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 106.91 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VRNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VRNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VRNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VRNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**